As part a major reorganization, Novartis CEO Vas Narasimhan created a new position overseeing the company’s corporate strategy. Now, he has found that leader in the form of a high-profile Wall Street analyst.
Longtime Sanford Bernstein analyst Ronny Gal, Ph.D., will join Novartis as chief strategy and growth officer, effective no later than Aug. 1, Novartis said Tuesday.
Gal brings more than 20 years of experience—including 17 years at Bernstein—in the life sciences industry from the financial research side, having provided some of the most insightful analyses of biopharma companies across a broad range of topics. Through the new role, the savvy sell-side analyst is tasked with leading Novartis’ corporate strategy, R&D portfolio optimization and business development.
“He is a thought-leader in the healthcare sector and is widely recognized for his deep thematic research across therapeutic areas, technology platforms and key industry topics such as the U.S. drug delivery system and efforts to reform it,” Novartis said of Gal in a statement.
Narasimhan described Gal as “one of the most seasoned and experienced analysts” of the biopharma sector. The Swiss pharma hopes Gal’s knowledge of therapeutic areas, technology platforms, clinical development and U.S. market dynamics could help the company shape its overall strategy, prioritize its internal pipeline and drive external opportunities, the CEO said during a press call Tuesday.